AHA Coding Clinic® for HCPCS - 2014 Quarter 2; For your information
Reporting instructions for GAZYVA (obinutuzumab)
GAZYVA™ (obinutuzumab ) injection for intravenous use in combination with chlorambucil, was approved by the U.S. Food and Drug Administration (FDA), for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). For facility reporting, the drug must be billed using C9399 and the drug information should be entered in the “Remarks” section of the UB-04 or electronic equivalent. Please note: As of April 1, 2014, HCPCS code C9021 , Injection, obinutuzumab, 10 mg, should be used to report GAZYVA (obinutuzumab) for facility reporting. ...
Subscribe or sign in to view the full article.
Article Overview
This short billing guidance article covers facility reporting for GAZYVA (obinutuzumab) in the context of FDA-approved use for a hematology/oncology indication. It is relevant to hospital outpatient and other facility coders who need to understand which HCPCS reporting approach is referenced and how the article frames the update date for that reporting guidance.
Why This Topic Matters
Facility coders and reimbursement staff may need to recognize the article’s reporting focus, the affected drug, and the cited HCPCS update so they can locate the applicable billing guidance without confusion.
What You Will Learn
- The article’s billing topic and setting
- The general context for reporting a specific oncology drug in a facility environment
- That an update date is mentioned for the reporting guidance
- Which coding system is referenced for facility drug reporting
Who Should Read This
- Facility coders
- Hospital outpatient billing staff
- Reimbursement specialists
- Oncology billing staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com